Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2024

Study Completion Date

November 8, 2024

Conditions
Neuroendocrine Tumor, MalignantLiver Metastases
Interventions
DEVICE

Bland Embolization

Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis

COMBINATION_PRODUCT

Transarterial chemoembolization

Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.

COMBINATION_PRODUCT

Drug Eluting Beads Embolization

CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.

Trial Locations (13)

10029

Mount Sinai School of Medicine, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

20132

Ospedale San Raffaele, Milan

33612

Moffitt Cancer Center, Tampa

53226

Medical College of Wisconsin, Milwaukee

77030

MD Anderson Cancer Center, Houston

94143

University of California San Francisco, San Francisco

94305

Stanford University, Standford

97239

Oregon Health & Science University, Portland

C1191 ABH

Hospital Italiano de Buenos Aires, Buenos Aires

M4N3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER